News
Bioxodes secures Orphan Drug Designation for hemorrhagic stroke therapeutic candidate in US and Europe
Bioxodes, a clinical stage biopharmaceutical company developing novel therapies for the prevention and treatment of thrombotic and inflammatory diseases, has received Orphan Drug Designation...
Lentitek secures £1m to advance next-generation cancer treatments
Edinburgh-based biotech company Lentitek has secured £700,000 in private funding from Equity Gap, a Scottish angel investment syndicate, bringing its total investment to £1...
Medigene and EpimAb Biotherapeutics to develop TCR-guided T Cell Engagers
Medigene and EpimAb Biotherapeutics have entered a strategic co-development agreement to research and develop off-the-shelf T cell receptor (TCR)-guided T Cell Engagers (TCR-TCEs) for...
